6634 ªYÄ£
ªÑ¥»: 3.832»õ
¥Dn·~°È:
¨xŦ¯e¯fªvÀø¤Î¯kµhªvÀø¬ÛÃöÃĪ«¬ã¨s¤Î¶}µo
¸³ºÊ«ùªÑ¤ñ¨Ò: 21.7%(¼W¥[¤¤)
¥~¸ê«ùªÑ¤ñ¨Ò: 0.22%(¼W¥[¤¤)
Ä~Äò©¹¤U¬Ý...!
=============================================================================
²£«~01¡GSNP-610 (ªvÀø¯×ªÕ¨x¯e¯f·sÃÄ)
¾AÀ³¯g: «D°sºë©Ê¯×ªÕ¨xª¢
²£«~Àu¶Õ:
1.¥Ø«e©|µL¼Ð·ÇªvÀøÃĪ«
2.¥«³õº¨£·sÃÄ(First-in-class)
3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x
4.µL¦w¥þ©Ê°ÝÃD
¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C
Ävª§¤O:
1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢
2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯×
3.¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x
¬ãµo¶¥¬q:
1.¤w³q¹LUSFDA¤ÎTFDA¼f¬d¶i¤JÁ{§É¤G´Á
2.Á{§ÉÀø®Ä¤Î·sªvÀø¾÷ÂàÅçÃÒ
Àø®Ä¤ÀªR¡G
1.²Ä¤@´ÁÁ{§É¸ÕÅç¡Gµ²ªGÅã¥Ü¤HÅé¨Ï¥Î¦w¥þ¡A©Ê½è¨}¦n
2.²Ä¤G´ÁÁ{§É¸ÕÅç¨ä¤¤¤ÀªR¡G17¦ìNASH ¯f¤H (p=0.009)
=============================================================================
²£«~02¡GSNP-630
¾AÀ³¯g:«D°sºë©Ê¯×ªÕ¨xª¢
²£«~Àu¶Õ:
1.¬°Àu¤Æ(Optimized)¤§·s¤Æ¾Ç¹êÅé(NCE)
2.¥«³õº¨£·sÃÄ(First-in-class)
3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x
4.§@¬°²Ä¤@¥N²£«~¤W¥««áªº±µÄò¦û¦³¥«³õ¤§²£«~
¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C
Ävª§¤O:
1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢
2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯×
3.Àu¤ÆªºÀø®Ä±j«×¡B§@¥Î®É¶¡
4.µL¦w¥þ©Ê°ÝÃD
¬ãµo¶¥¬q:
1.Á{§É«e
2.¹w©w¥Ó½Ð¬ü°êFDAIND¡B§Ö³t³q¹D(fasttrack)¡C
3.¥Ó½Ð¬ü°ê¬ð¯}©ÊªvÀø(breakthrough therapy)ªº»{©w¡C
Àø®Ä¤ÀªR¡G
1. ¥Ø«e¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.05
=============================================================================
²£«~03¡GSNP-810 (µL¨x¬r©Ê¤îµh·sÃÄ¡B¸Ñ¬r¾¯)
¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃÄ (¸Ñ¼öÂíµh¾¯)
²£«~Àu¶Õ:
1.¦w¥þ¤Æ¦Xª«·s²Õ¦X¡BµL¨x¬r©Ê
2.¸Ñ¨M¢¤ÁÂåÀø»Ý¨D (Important urgent unmet medical needs)
3.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¥i¼W¥[¾¯¶q
¥«³õ: ¤AñQÓi×ô¶È¦b¬ü°ê¤@¦~´N¦³40»õ¬ü¤¸ªº¥«³õ
Ävª§¤O:
1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«
2.¥i§ð¦û¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^
3.¥i¬Ù°£¶D³^¶O¡B±Ð¨|°V½m¶O
¬ãµo¶¥¬q:
1.¤w§¹¦¨§C¾¯¶q¡B°ª¾¯¶qÁ{§É¸ÕÅç
2.¤w¥Ó½ÐUSFDA¼Ï纽Á{§É¸ÕÅç¡B±N¥Ó½Ð¬ð¯}©Ê¼f¬d/§Ö³t³q¹D
3.µL¨x¬r©Ê¤AñQÓi×ô¸Ñ¬r¾¯¦¨¤À¡A¤w¥Ó½Ð¬dÅçµn°O¥Î¤§Á{§É¸ÕÅç
=============================================================================
²£«~04¡GSNP-830/ SNP-840
¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃĽƤè(ªvÀø¤¤¡B««×¯kµh)
²£«~Àu¶Õ:
1.µL¨x¬r©Ê¤AñQÓi×ôªº½Æ¤è
2.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¡A¥i¼W¥[¾¯¶q
¥«³õ: ¤AñQÓi×ô³B¤èÃĦb¬ü°ê¤@¦~´N¦³27»õ¬ü¤¸ªº¥«³õ
Ävª§¤O:
1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«½Æ¤è
2.½Æ¤è¤w¥Ñ¬ü°êFDAn¨D°¾¯¶q§C©ó325²@§J¡A±N¼vÅTÀø®Ä
3.¦³¨Ï¥Î±M§Q¡A¥iקï©Î§R°£FDA¨x¬rĵ»y
4.¥i¼W¥[¤AñQÓi×ô¾¯¶q
¡]¥Ñ325mg ¦^´_¦Ü500 mg¬Æ¦Ü§ó°ª¡A·|¸û¦³®Ä¡^¥H¼W¥[Àø®Ä¡A©Î´î¤ÖOpioids¾¯¶q¡A°§C¦¨Å}°Æ§@¥Î
5.¤GªÌ¾Ü¤@±ÂÅv
6.¥i¼W¥[¥«¦û²v
¬ãµo¶¥¬q:
1.SNP-810¨ú±oÃÄÃÒ«á¡A¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê¸ÕÅç
SNP-830 ¤£¬O ·s¦¨¤À ªº·sÃÄ¡A©Ò¥H¤£»Ýn¶i¦æ²Ä¤@¡A¤G¤Î¤T´ÁÁ{§É´úÅç
µ¥ SNP-810 ®³¨ìÃÄÃÒ«á¡A¥H ·sÀø®Ä½Æ¤è¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê´úÅç ´N¥i¥HÀò±oÃÄÃÒ
=============================================================================
*****************************************************************************
SNP-8 ¨t¦C Àø®Ä¤ÀªR¡G
1. ¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005
1. ¤w¸g§¹¦¨¤§¤HÅé¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005
=============================================================================
*****************************************************************************
¥¼¨Ó¥Ø¼Ð±ÂÅv¥D¤O²£«~¡G
1. ¯×ªÕ¨xÃÄ¡GSNP-610 ©M SNP-630 ¦U¦³ÀuÂI¡A¥Ø¼Ð¬°¥þ²y±ÂÅv
2. ¤îµhÃÄ(OTC): SNP-810, ¥Ø¼Ð¬°¬ü°ê¤Î¥þ²y±ÂÅv
3. ¤îµhÃÄ(³B¤èÃÄ): SNP-830 ¤Î SNP-840, ¦b°Êª«¤W¬Ò¦³¥¿±ªºµ²ªG¡A¥Ø¼Ð¬°¥þ²y±ÂÅv
=============================================================================
*****************************************************************************
¥Ø«e¤½¥q»P°ê»Ú¤j«¬Ãļt¥¿¦b½Í§Þ³N±ÂÅv©M¦X§@p¹º
§Ú¬Ý¹L¤½¥q©xºô©M©Ò´£¨Ñªº¸ê®Æ¡Aı±o¤½¥q«Ü¥Î¤ß¦b¸gÀç¡A¦Ó¥B¸ê®Æ¤]«Ü¸Ô²Ó
¹ï¤½¥qµo®i«Ü¦³¦Û«H¡A¥¼¨ÓªÑ»ùȱo´Á«Ý¡A¦³¾÷·|¬O ¤U¤@Ó ¦X¤@ ÄƪÑ
-----------------------------------------------------------------------------
¥H¤W¸ê®Æ ³£°Ñ¦Ò ªÑªF·|ij¨Æ¿ý.pdf ©M ¤½¥q©xºô (¦³¿³½ìµÛÅwªï¦A²`¤J¬ã¨s»P°Q½×)
¤£¬O¦³¤j²³¤£ª¾¹Dªº§QªÅ. ´N¬O¦ÑÁó¥u ¨I°g¬ãµo¤£¦b·NÀò§Q. ³Q¨ÖÁÊÀ³¸Ó¾÷·|´ù¯í, ¯à¦b1¦~¤º½Í ¤U±ÂÅv´N¤Ó©¯ºÖ¤F.
§Ú¤£t³d¥ô:À³¸Ó¬O¤j¼t¶}»ù§C¡A©Ò¥HJP»¡¤£½æ!
----------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/9 ¤U¤È 08:52:57²Ä 1956 ½g¦^À³
05_·sÃĶ}µo_¿ïÃD
J¤j¯«¦b14:15¬í°_:...½Í¨ì³Ì«á ¥L»¡±z̯ण¯à ³o®a.§Ú´N¶R±z̪ºªÑ²¼°Ú.§ë¸ê±z̪ºªÑ²¼°Ú...§Ú»¡ ¥xÆWªºªÑ²¼¤Ó«K©y..¹ï¤£°_ ¤£¦æ ±zn´N¶Rcompound ±z·Q¶R[¤½¥q] §Ṳ́£½æ±z....½Í¨ì³o¼Ë£²...
----------------------------------------------------------------------------------------------------
www.labroots.com/trending/cell-and-molecular-biology/24677/major-insights-nash-severe-type-fatty-liver-disease
...¬ã¨s¤Hû¦b¥L̪º¤p¹«¼Ò«¬¤¤¨Ï¥Î siRNA °±¤î¤F RIPK3 ªºªí¹F¡C³oªí©ú¡A
[¤@¥¹ RIPK3 ¤£¦Aªí¹F¡A§Y¨Ï¦b±w¦³ÄY«¯×ªÕ¨xªº°Êª«¤¤¡A¨x²ÓMªº¦º¤`©M¨x·l¶Ë¤]·|°¦Ü³Ì§C¡C]
[¥¹ RIPK3 ¤£¦Aªí¹F¡A§Y¨Ï¦b±w¦³ÄY«¯×ªÕ¨xªº°Êª«¤¤¡A¨x²ÓMªº¦º¤`©M¨x·l¶Ë¤]·|°¦Ü³Ì§C¡C]
2023.1.23- www.nature.com/articles/s41467-023-35804-w
..§Ú̳q¹L¨x²ÓM RIPK3 ªº¥\¯à³à¥¢½T©w¤FÃa¦º©Êä¤`¦bÄY«¨x¯×ªÕÅܩʤ¤ªº«n©Ê¡C
--------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/12/17 ¤W¤È 10:30:19²Ä 2732 ½g¦^À³
¦A¤@½g²Ï¹êªº¾Ç³N¬ã¨s¡AÅýSNP610/SNP630(CYP2E1)ªºNASHÁ{§É¦¨¥\²v¤j¼W¡C
....
·|û¡GROGER588910148151 µoªí®É¶¡:2022/12/12 ¤W¤È 10:03:20²Ä 2709 ½g¦^À³
³Ìªñµoªíªº´X½g½×¤å...
¬ã¨sªí©ú¡ACYP2E1 ¹ï RIPK3 ªºªí¹F°µ¥X¤F«¤j°^Äm....ªí©úCYP2E1 §@¬° RIPK3 ªº¤W´å°^ÄmªÌ...
¦³¸Ó¤½¥q·Qnªº¤£¶Ë¨x810
NASHªº610¤Î630
¦¬ÁÊMadrigal nªá¤j¿ú
¦¬ÁʪYÄ£¬Û¤ñ¥unªá¤p¿ú
ARO -HSD °§CºÃ¦ü NASH ±wªÌªº¨xŦHSD17B13 mRNA ªí¹F©M³J¥Õ½è¤ô¥¡C
ir.arrowheadpharma.com/static-files/b6b66255-5618-4706-96f2-e0fbfc68ce75
-----------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/12/4 ¤U¤È 05:01:34²Ä 2705 ½g¦^À³
NASHªºµo¯f¾÷¨î¤Ó½ÆÂø¡A·sªº¬ã¨sµ²ªG¤£Â_´é²{¡AGSKªá10»õ¬ü¤¸±ÂÅvªºÃĪ«¡A¤p¹«¼Ò«¬²£¥Í¤F¤£¤@Pªºµ²ªG¡AÁÙ¦Ûµoµo®i¬°¿ðµo©Ê¯×ªÕ¨x¡C
1. 2021.3.16 Hsd17b13 ¯Ê³´¤£¯à«OÅ@¤p¹«§K¨üPªÎD©Ê¶¼¹·l¶Ë
www.ncbi.nlm.nih.gov/pmc/articles/PMC8627256/
2. 2022.7.16(2011¦~¿Õ¨©º¸¥Í²zÂå¾Ç¼ú±o¥DBruce Beutlerªº½×¤å)
www.nature.com/articles/s41467-022-31812-4
...³Ìªñªº¤@½g½×¤å³ø¾É¤F¤@Ó¤£¦PªºÆ[¹îµ²ªG¡A§YHsd17b13°ò¦]ºV°£¤p¹«¦b´XºØ¯×ªÕ¨x»¤¾Éªº¶¼¹±ø¥ó¤U¡A¦b¨x¯×ªÕÅÜ
©Ê¡B¨x·l¶Ë¡BÅÖºû¤Æ©Mª¢¯g¤è±»P WT ¤p¹«¨S¦³®t²§!
3. 2022.1.7 («nì³ÐªÌ:Ĭ¤å) www.ncbi.nlm.nih.gov/pmc/articles/PMC8776652/
¥O¤HÅå³Yªº¬O¡A³Ìªñ¹ï HSD17B13 °ò¦]ºV°£¤p¹«ªº¬ã¨sªí©ú¡AHSD17B13 ¯Ê¥F¯g¥¼¯à«OÅ@¨xŦ§K¨ü°ª¯×ªÕ¶¼¹¡B¦è¤è¶¼
¹©M°sºë¼ÉÅS¤Þ°_ªº¯×ªÕÅÜ©Ê·l¶Ë¡A³oªí©ú HSD17B13 ¯Ê¥F¯g¥i¯à¹ï¤p¹« NAFLD ¨S¦³«OÅ@§@¥Î¼Ò«¬¡C¦P¼Ë¡A¥t¤@²Õ³ø
§i»¡¡A¯Ê¥F HSD17B13 °ò¦]ªº¤p¹«¦b 9 Ó¤ë¤j®É¦b¥¿±`¶¼¹¤U¦Ûµoµo®i¬°¿ðµo©Ê¯×ªÕ¨x.³o¨Ç·N·Q¤£¨ìªºµ²ªG¥Ø«e¯Ê¥F
¾÷¨î¸ÑÄÀ¡A»Ýn¶i¤@¨B¬ã¨s¡C
§Ú¤£t³d¥ô²q´úì¦]: 1.JNJ-75220795¼Æ¾Ú¤£¦p¹w´Á? 2.¹w³Æ¥X¤â¦¬ÁÊMadrigal©Îintercept?
1. 2023.2.8-- (J&J)¼b¥Í¥þ²y·~°È¤j¾ã¹y¡I 37»õ¬ü¤¸¶R¤UArrowhead B¨xÃÄ®£³Q±ó¡H
news.gbimonthly.com/tw/article/show.php?num=56115
2. 2023.2.15-- Janssen ±N I ´Á NASH(JNJ-75220795)Ô¿ïÃĪ«ªð¦^ Arrowhead
www.fiercebiotech.com/biotech/jj-strikes-down-nash-pact-arrowhead-hep-b-deal-still-limbo
-------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2021/11/29 ¤U¤È 05:37:52²Ä 1489 ½g¦^À³
¬d²z.»X®æ:°ªÃBªº³ø¹S¨Ã«D¨Ó¦Û©ó¶R½æ¡A¦Ó¬O¦s¦b©óµ¥«Ý¤§¤¤¡C
2020.12.22 ªYÄ£»P°ê»ÚÃļtñSNP-810¬ãµo¦X§@¨óij
VS
2018.10. 04 Arrowhead »P Janssen ¹F¦¨ 37 »õ¬ü¤¸ªº³\¥i©M¦X§@¨óij
(JanssenÀò±o3Ó¦X§@¶µ¥Ø:ARO-JNJ1 ;ARO-JNJ2;ARO-JNJ3)
ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-enters-37-billion-license-and-collaboration-agreements
¸g¹L 1¦~2¦~3¦~
2021 ¦~ 1 ¤ë 17 ¤é-- Arrowhead¤µ¤Ñ«Å¥¬¨ä¦X§@ªÌ¡A ·¨´Ë»sÃĤ½¥q, (Janssen) ±j¥ÍºX¤Uªº Janssen »sÃĤ½¥q¤§¤@¡A¤w©ÜÅS»P Arrowhead ´N¬ã¨s¤Æ¦Xª« JNJ-75220795 ªº¦X§@
¸g¸ß°Ý¥DºÞ¾÷Ãö¡A®Öã¸ÕÅç®×¥ó§¡µn¸ü©ó»OÆWÃĪ«¸ÕÅç¸ê°Tºô¡C
¸Óºôµn¸üªº²Ä¤@¶µ¦h¾¯¶q¸ÕÅç36¤H¦Ü2023¦~12¤ë31¤é¤î¡C
±©¸Óºô¶Áöµn¸ü¬°¡u¦h¾¯¶q¡v¡A«o¶È¦³500²@§J¡u³æ¾¯¶q¡v¡C
¨Ã¥¼µn¸üÄÝ©ó4-8§J¤§¨ä¥L¾¯¶q¡A¡u¦h¾¯¶q¡v¡B¡u³æ¾¯¶q¡v©úÅ㤣²Å¡C
¡u¥l¶Ò¤¤¡v
Ó¤H±À´ú¬O¦P¤@Ó¸ÕÅç
¥t610-2¤]¸ò¤W¤S¤U¬[ºô¶®É¶¡¤@¼Ë¦Ü114¦~¡A¤H¼Æ80¤H¡C
¡X¡X¡X¡X
¨â¤j¼t¥»´N¦³Ã±¦X§@¦X¬ù-¸ÕÃÄ®Ä
A¤½¥qÃĮĸÕÅç¤w³q¹L
B¤½¥q¦X¬ù¨ì´Á¡A¥¼§¹¦¨ÃĮĸÕÅç¡C
¨º¤Ñ¤W¤S¤U¬[ªººô¶
¦³B¤½¥q¥¿¦b¶i¦æÃĮĽT»{
³B¤èñªº¼Ï¶s¹LÃö
Ó¤H»{¬°»ùȬOOTCÃÄÃÒ©Ò¤£¯à¤ñ
¬ü°ê¼Ï¶s¸ÕÅç¬O³æ¾¯¶q
ì¥Ó½Ð¤ñ¼Ð·Ç¾¯¶q°ª
«á¨Ó¬ün¨D¤j¹«¸ÕÅç
¤½¥q¥¼ÁקK¼vÅT¸ÕÅç
¦n¹³§ï¬°¼Ð·Ç¾¯¶q
¥un»OÆW¼Ï¶s¹LÃö
±ÂÅv´N¦n½Í¡A¬ü¸ÕÅç¤]·|§ó¶¶§Q¡C
---------------------------------------
§Ú¤@ª½Ä±±o ¨ä¹ê³o´N¬O¦bÁ¿ª¯ªº¹êÅç ±Ôz¤£²M ³æ¦ì¥Î¿ù
´Nºâ³o¬O810¦b¥xÆWªº¼Ï¯Ã(¤H) §Úı±o2¤j¼tÁÙ¬O¤£·|¶R³æ ¥¦ªùn¬Ýªº¬O¬ü°ê¼Ï¯Ã
³o¨Ç±Ôz¬O¤½¥q¨º¤Ñ¤W¬[¨S¦h¤[¤S¤U¬[ªº¤º®e
¨º®É±z¤]po¤F¥ÎÃÄ7¤Ñªº¸ê°T
¨ì©³¬O¤°»ò¡Hn°Ý¦¶¸³¡I
¤S¬°¤°»ò¤S¤U¬[¡H
¬O¤£¬O¥h¦~³oÓ¤½§i¸ÕÅçµ²ªG¡I
....810ªº¼Ï¶s¸ÕÅç¡A±q¡u¦h¾¯¶q¤À²Õ¡A¨C²Õ14¤H¡A³Ì¤Ö6¤H¦¸¡A¤w§¹¦¨12¤H¦¸¡v¡u¥ÎÃÄ7¤Ñ¡A¤£¶Ë¨x¡Aµ²ªG²Å¦X¹w´Á¡v
¡u¸ÕÅç³ø§iÄ¡¼g¤¤¡vµ¥µ¥¡A±À¦ô¼Æ¾Ú¥¿¦V¡A·¥¦³¾÷·|¦bµu´Á¶¡¤º¤½§iµ²ªG¡C
------------------------------------------------------------------------------------------------
¤W±À³¸Ó¬O«ü111/10/20ªº¤½§i:
1.¨Æ¹êµo¥Í¤é:111/10/20
2.¤½¥q¦WºÙ:ªYÄ£¥ÍÂåªÑ¥÷¦³¤½¥q
3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q
4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î
5.µo¥Í½t¥Ñ:
¥»¸ÕÅçÄݩ󥻤½¥qSNP-810[¼Ï¯Ã©ÊÁ{§É]ÅçÃÒ¸ÕÅ礧¤@¡A¸ÕÅç³]p¬O¦h¾¯¶q¡B³æª¼¡B³æ¤¤¤ß
¤Î¤fªAµ¹»P´¶®³¯k©ÎµL¨x¬r©Ê¤îµh·sÃÄSNP-810¤§Á{§É¦w¥þÅçÃÒ¸ÕÅç¡A§ë»P¾¯¶q4-8§J¡A
¸Ó¸ÕÅ羯¶q¤w¶W¹L²{¦æ¤AñQÓi×ô(Acetaminophen)ÃÄ«~»¡©ú®Ñ®Öã¨Ï¥Î¨C¤é³Ì¤j¾¯¶q¡A
¹wp§¹¦¨36¦ì¨ü¸ÕªÌ¡A¨ú±oÁ{§É¦w¥þµ²ªG«á¡A¦A¦V½ÃºÖ³¡¹Ãĸp¿Ô¸ß·sÃÄ®Öã¤W¥«¡C
--------------------------------
(§Ú¦b¥xÆWÃĪ«Á{§É¸ÕÅç¸ê°Tºô¬d¤£¨ì36¦ì¨ü¸ÕªÌªºÁ{§É?)
²{¶¥¬q´Á«Ý810±ÂÅv¤ñ¸û°È¹ê.§Ú¬Ý3¤ë¥Ó½ÐIPO¤WÂd¡AÀ³¸Ó¾÷²v¤£¤j¡D¨S¦n»ù¿ú¡D
¥Ø«eNASH·sÃĸÕÅç¡A´X¥G³£¦³°Æ§@¥Î¡C
I¤½¥q¬J¨Ï3´Á¹F¼Ð¡A¥Ñ©ó°Æ§@¥Î¤Ó¤j¡A¥Ó½ÐÃÄÃÒ³Q»é¦^¡C
M»PA¤½¥q¤]³£¦³°Æ§@¥Î¡A¤j®aÃIJz¾÷Âà´X¥G¬Û¦ü¡A¬G±À610¤]¨ã¦³¦P¼Ë°ÝÃD¡C
630°µ§¹1´Á¡AºÙ¨S¦³°Æ§@¥Î¡A¤½¥q¥»¨Ó¥i¯àp¹º¥H610ÅçÃÒÃĮīán¥D§ð630¡AµL©`¦X¦¨§xÃø¡A¦¨¥»¤Ó°ª¡A¦h¦~¥H¨Ó¡AµLªk¸Ñ¨M¦X¦¨¦¨¥»ªº°ÝÃD¡C
ì±ÀM¤½¥q3´Án¨ì2024¦~¡A¤£±o¤£¤Ï¹L¨Ó¥ý°µ610¡A¤~¯à»°¤W«e´X¦W¡A¦]¤j®a§¡¨ã°Æ§@¥Î¡A³o´Á¶¡¦A´M¨D630¦X¦¨°ÝÃD¡A§ä¨ì¤èªk«á¦A°µ630ªº2´Á¡C
³o¥i¯à¬ON¤j©Ò»¡ªº¥dÃö¡H
810ªº¼Ï¶s¸ÕÅç¡A±q¡u¦h¾¯¶q¤À²Õ¡A¨C²Õ14¤H¡A³Ì¤Ö6¤H¦¸¡A¤w§¹¦¨12¤H¦¸¡v
¡u¥ÎÃÄ7¤Ñ¡A¤£¶Ë¨x¡Aµ²ªG²Å¦X¹w´Á¡v
¡u¸ÕÅç³ø§iÄ¡¼g¤¤¡vµ¥µ¥¡A±À¦ô¼Æ¾Ú¥¿¦V¡A·¥¦³¾÷·|¦bµu´Á¶¡¤º¤½§iµ²ªG¡C
¦pªG¼Ï¶s¸ÕÅçµ²ªG¡A¥¼¦b3¤ëªì¤½§i¡A«hIPO·|©µ«á¡Aµ¥¨ì¼Ï¶s¹LÃö«á¦A«·s¥Ó½Ð¤u·~§½°ª¬ì§Þ¦P·N¨ç¡C
¼Ï¶s¸ÕÅç¹LÃö¡A¦A½Í±ÂÅv»ù½X¤~·|°ª¡C
¥H¤W¬OÓ¤H¬Ýªk¡A¶È¨Ñ°Ñ¦Ò¡I
SNP-610²{°µªºP2¬dÅçµn°O¥ÎÁ{§É¡A¤£¬O«§@¤G´Á!
-----------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/9/25 ¤U¤È 06:13:11²Ä 2543 ½g¦^À³
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/12 ¤W¤È 09:52:26²Ä 2236 ½g¦^À³
¦³¤Ö¼Æ¤p¤À¤lÃĦX¦¨¨BÆJ¦h¥B²£²v·¥§C¡A¦¨¥»°ª©ó¤j¤À¤lÃÄ!(SNP-630«ÜÃø¦X¦¨!!!)...
--------------------------------------------------------------------------------------
1.©e°U¬ã¨s °]¹Îªk¤H¤¤µØ´º±dÃľǰòª÷·|110/5/1~111/4/30 SNP-630ÃÄ«~¤Æ¦Xª«(¦X¦¨Àu¥ý)©e°U§Þ³NªA°È
2.©e°U¬ã¨s »OÆW¤j¾Ç 110/7/1~111/6/30 SNP-630¦X¦¨ÃÄ«~¬ã¨spµe®Ñ
SNP-630«ÜÃø¦X¦¨¬OÁô¼~¡A§Æ±æ¦³¬ð¯}!
--------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤W¤È 11:24:48²Ä 2160 ½g¦^À³
¬Ý¬Ý¯E¹©¡ASNP-630¦¨¥»¬OÁô¼~?!
«¥Ó630¦w©w©Ê»P¦¨¥»©|«Ý¸Ñ¨M¡A²{¦b610¤Sn°õ¦æ2b¤F¡H»¡¥Õ¤F¤]¬O¥dÃö
SNP-610/SNP-630(CYP2E1§í¨î+DGAT1§í¨î)
°£¤FAPAP¸Ñ¬r¡A§Æ±æ¦³Ãļt¦³¿³½ì¶}µoSNP820¦b¤ß¦åºÞ¯e¯f(DCM...)»P¸£¯«¸g¯e¯f(©¬ª÷´Ë¤ó¯g/ªü¯÷®üÀq¯g...)Á{§É!
-------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/6 ¤U¤È 12:01:05²Ä 2846 ½g¦^À³
CMZ can only be given for a short period of time and therefore other CYP2E1 inhibitors to treat ALD are needed.
CMZ can only be given for a short period of time and therefore other CYP2E1 inhibitors to treat ALD are needed.
.
1. 610 2a«°µ©Î¸É°µ, ¥[¤W2b¥i¯àn3-5¦~.
2. 610Á{§É2´Á§@§¹«e«ÜÃø§ä¨ì±ÂÅv.
3. ±ÂÅv¥i¯à¥u³Ñ8¨t¦C.
4. 8¨t¦C¥«³õ³W¼Ò¤Î»ùÈ»·§C©ó6¨t¦C.
§Ú쥻§ë¸ê¶R¶i¬O»{¬°:
1. 1¦~¤º¦³¾÷·|½Í¦¨8¨t¦C±ÂÅv.
2. 2¦~¤º6¨t¦CÁ{§É2¥i§¹¦¨.
²{¦b±¡¶Õ, ¤j®a»{¬°¸ÓÄ~Äò¶R¶i¶Ü? ÁÙ¦³ºô¤Í»{¬°¥i¼Ú¦L¶Ü?
§Ú쥻¶R¶i®É¥´ºâ«ù¦³2¦~, ²{¦b¬Ý¥i¯à¸Ó3-4¦~.
SNP610(CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[:¤@¥¹ CYP2E1 ³Q§í¨î¡A¨xŦ¤¶¾Éªº CYP2E1 ¤º·½©Ê¥NÁª«¡]¥]¬A LysoPC 22:4¡BDHA¡BAA ©M LCA¡^ªº¥NÁ´N·|´î®z¡A±q¦Ó¨Ï³o¨Ç¤Æ¦Xª«¦b¨x²ÓM¤¤¼W¥[!
¤t¤j团队报¹D脑¯Ê¦å¦AÄéª`¤¤¾®¦å酶诱导ACSL4¨Ì赖©Ê铁¦º¤`
k.sina.com.cn/article_5803416260_159e91ac4019011n89.html
®ñ¤Æ应¿E¡C随þÓROS¤É°ª¡A§Ü®ñ¤Æ剂¨t统ªº¨¾±s¯à¤Oú£®z¡A§Ü®ñ¤Æ剂酶¥¢¬¡©M§Ü®ñ¤Æ剂®ø¯Ó¡C这会导P¦hÏú¦³®`¨Æ¥ó¡A¨Ï¯«经¤¸ä¤`©M§¥¦º¡C¡@¡@这´N¬O为¤°¤\针对®ñ¤Æ应¿E¬O¤@Ïú¦X²zªºªv疗¤èªk¡A¯S别¬O¡A铁¨Ì赖©Êªº铁¦º¤`³q过过¶qªº¯×质过®ñ¤Æ导P细M¦º¤`¡A这¥i¯à导P脑¨ò¤¤¤¤¯«经¤¸ªº¦º¤`¡C
.....
§@ªÌ§Q¥Î¯×质¥N谢组学¡B³J¥Õ质组学©M§K¬Ì组¤Æµ¥¤â¬q¡A
发现¾®¦å酶¤Î¨ä[ªá¥Í¥|²m»Ä][ªá¥Í¥|²m»Ä][ªá¥Í¥|²m»Ä]¥N谢¤U´åªºACSL4]¬O参ÉOI/R¤¤铁¦º¤`诱导ªº细M¦º¤`³q¸ô¤¤ªº关键³J¥Õ¡]图1¡^¡A从¦Ó对¯Ê¦å©Ê脑¨ò¤¤铁¦º¤`ªº¥Íª«学Éó¨î¦³¤F·sªº认识¡A该³q¸ô¥i¯à为ªv疗¯Ê¦å©Ê脑¨ò¤¤´£¨Ñ·s³~径¡C
--------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/28 ¤U¤È 05:22:04²Ä 2031 ½g¦^À³
ªYÄ£¥²nÅçÃÒ³o½g½×¤å´£¥Xªº¾÷¨î:SNP610(CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21)¡C
m.medsci.cn/article/show_article.do?id=7177291544ec
....
[铁¦º¤`]¬O¤@Ïú¥Ñ¨Ì赖¤_[ROS]©M细M内铁¶W载ªº[¯×质过®ñ¤Æ§@¥Î]¤Þ°_ªº·sªº独¯Sªºµ{§Ç©Ê细M¦º¤`§Î¦¡¡A¦ý¨ä许¦h¥Í²z§@¥Î©|«Ý©úÚÌ¡C¥Ø«e¤w经¦³¨¬û{ªº证Õuªí©ú¡A¦b¯«经°h¦æ©Ê¯e¯f´Á间ÚÌ实发¥Í¤F铁¦º¤`¡A¦}¥B³q过¹v¦V铁¦º¤`ªº调节剂ªv疗¯«经°h¦æ©Ê¯e¯f¤w³Q证©ú¬O¥i¾aªº¡C
---------------------------------------------------------------------------------------------------
Q&A:¶Q¤½¥qªº¯×ªÕ¨xª¢ÃĪ«¦³¦ó¯S®í¤§³B¡H
SNP-6¨t¦C¤£¶È¨ã¦h«¾÷Âà¡A§ó¥i¤À§O°w¹ï¥H¤U¤T¤jÃþ¾÷ÂàªvÀø/¹w¨¾¯×ªÕ¨xª¢¬ÛÃö¯f¯g¡G
(1) ½Õ±±¨x¯×ªÕ¥NÁÂ
(2) §Ü¯×ªÕ¨xª¢
SNP-6¨t¦C¥iª½±µ§í¨î¨xŦCYP2E1¬ÛÃö»Ã¯À¡B°§CCYP2E1¬ÛÃö°ò¦]ªºmRNA©M³J¥Õªí²{¶q¡A¨Ï±o·|¶Ë®`¨x²ÓM¡B»¤µoµoª¢¤ÏÀ³ªº¬¡©Ê®ñ¤Æª«½è(Reactive oxygen species, ROS)¤£¦A²£¥Í©Î°§C¡A¶i¦ÓªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢¡C
[ÅK¦º¤`]©MAPAP(¹ï¤AñQÓi×ô)»¤¾Éªº«æ©Ê¨x·l¶Ë
...GSH¤U°¡BÅK¹L¸ü©M¯×½è¹L®ñ¤Æ³Q»{¬°¬O°ò¥»ªºAPAP ¤Þ°_¨x·l¶Ëªº¾÷¨î¡C¶V¨Ó¶V¦hªº¬ã¨s¤Hû¤w¸gÃÒ¹êÅK¦º¤`°Ñ»P APAP »¤¾Éªº²ÓM¦º¤` ..... Á`¤§¡AÅK¦º¤`¥i¯à¦b APAP »¤¾Éªº«æ©Ê¨x·l¶Ë¤¤µo´§«n§@¥Î¡A§ó¦n¦a¤F¸ÑÅK¦º¤`ªº½Õ¸`§@¥Î¥i¯à´£¨Ñ¼ç¦bªºÁ{§ÉªvÀø¤èªk¡C
¦Û2012¦~[铁¦º¤`]¤@词³Q´£¥X¥H来¡A[铁¦º¤`]¤Þ°_¤F¤H们ªºÆΪx关ª`¡C(¤@Ïú·sªºªüûدý®üÀq¯f°²说)
1.Nature综z|铁¦º¤`¦b¯e¯f¤¤ªº发¯fÉó¨î¡B¥Íª«学©M§@¥Î
m.ebiotrade.com/Newsf/2021-10/20211022070102716.htm
2.2022.3.26-«½S综z¡I铁¦º¤`¦b©¬ª÷´Ë¯f¤¤ªº§@¥Î news.bioon.com/article/f7cde232405a.html
©¬ª÷´Ë¯f(PD)¥H¦h¤ÚÓi(DA)¯à¯«经¤¸丢¥¢©MM浆³J¥Õ¥]²[Ê^§Î¦¨为¯S©º¡C尽ºÞ©¬ª÷´Ë¯fªºṲ́Á发¯fÉó¨î©|¤£²M·¡¡A¦ý铁
¥N谢¯¿乱¤w³Q认为¬O¤@个ýͦbªºP¯f¦]¯À¡C·sªº证Õuªí©ú¡A¯«经胶质细Mªº¿E¬¡¦b铁¦º¤`©M随¦Zªº¯«经°h¦æ©Ê变¤¤°_þÓ关
键§@¥Î¡C
3. 2021.9.30-铁¦º¤`ªº发¥ÍÉó¨î©M¬ã¨s«ä¸ô¬O¡H
www.cn-healthcare.com/articlewm/20210930/content-1269610.html
¬ã¨sI´º:铁¦º¤`¬O铁©M¬¡©Ê®ñ¡]ROS¡^¨Ì赖©Êªº调节©Ê细M¦º¤`§Î¦¡¡A¬O¤£¦P¤_细Mä¤`¡B细M§¥¦º¡B细M¦Û¾½ªº·s«¬细
M¦º¤`¤è¦¡¡C
铁¦º¤`发¥ÍÉó¨î:铁¦º¤`ªº发¥Í¬O细M内¯×质¬¡©Ê®ñ¡]ROS¡^¥Í¦¨ÉO°¸Ñªº¥¿Å¥¢调©ÒP¡C
4.铁¥¢¿Å©M铁¦º¤`¡G¥i¯à¬O¤@Ïú·sªºªüûدý®üÀq¯f°²说 zhuanlan.zhihu.com/p/488318042
------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/23 ¤U¤È 10:48:06²Ä 2256 ½g¦^À³
ªñ¦~¨Ó¡A²ÓM¦â¯À P450 酶 (CYP) ªº«n©Ê¤w¶W¥X¨ä¦b¨xŦ¤¤ªº§@¥Î???
CYP2E1 ¬O¤@ºØ¤½»{ªº°Ñ»P¦UºØ¤º·½©Ê©M¥~·½©Êª«½è¥NÁªº³æ¥[®ñ酶¡A¦b¯A¤Î©¬ª÷´Ë¯fµo®iªº¤j¸£¤¤°_µÛ¦ÜÃö«nªº§@¥Î¡C
CYP2E1ªº [¹Lªí¹F]¦ü¥G¹ï¦h¤ÚÓi¯à¯«¸g¤¸¦³®`....
±EÀu?(SNP-610/SNP-630²æ¹v?)
---------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/28 ¤U¤È 05:22:04²Ä 2031 ½g¦^À³
ªYÄ£¥²nÅçÃÒ³o½g½×¤å´£¥Xªº¾÷¨î:SNP610(CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21)¡C
2022.5¤ë www.sciencedirect.com/science/article/pii/S2211383522000545
¥Ñ©ó CYP2E1 ¥Dn¦b¥Dnµo¥Í¥NÁªº¨x²ÓM¤¤ªí¹F¡A¹v¦V§í¨î CYP2E1 ¥i¯à¹ê²{ì¦ì¨x²ÓM¤¤ªº PPAR £\¿E¬¡¡A³o¥i¥HÁ×
§KÁ{§É¤¤°¸º¸µo¥Íªº«D²Õ´¯S²§©Ê PPAR £\¿E¬¡ªº°Æ§@¥Î--->SNP-610Àø®Ä¦w¥þÀu©óElafibranor (PPAR£\/£_¿E动剂)
®ü¥Í¬ì°|µ¥发现FGF21¦b缓¸Ñ内质ÊI应¿EÉO¯×ªÕ¨x¤¤ªº§@¥Î¤ÎÉó¨î (AkeroªºEfruxifermin¬OFGF21Ãþ¦üª«) www.cas.cn/ky/kyjz/201411/t20141119_4255383.shtml
MadrigalªºResmetirom(THR-£]¿E°Ê¾¯)¬OF2~F3¨úÃÒ¡AF4¥[ºòÁ{§É¸ÕÅ礤!
---------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/12/21 ¤U¤È 03:26:06²Ä 2745 ½g¦^À³
...«ö¥Ø«e¼Æ¾Ú¡A²Ä1¤ä¦b«D¨xµw¤ÆF2~F3 »P¨xµw¤ÆF4¤jº¡³e¨úÃÒªº¬OAkeroªºEfruxifermin¾÷²v¸û¤j¡C
Cyp2e1¡A¥Dn¤À§G¦b²É½uÅ餺½¤©Î¬O¤º½èºô¤W¡C¨x²ÓM¤º¦s¦b¤j¶qªº¤º½èºô¡A³\¦h¨xŦ¬ÛÃö¯e¯f§¡»P¤º½èºôÀ³¿E¦³Ãö¡C
CYP2E1¬O²£¥ÍROS(®ñ¤ÆÀ³¿E)³Ì¥DnªºCYP¨È«¬¡C
1.2022.11.14诺奖级¬ã¨s¡§内质ÊI应¿E¤Ï应¡¨¡Aªì创¥ø业ºËã临§É试验
www.keguanjp.com/kgjp_keji/kgjp_kj_smkx/pt20221114000002.html
将¡§内质ÊI应¿E¤Ï应¡¨¥Íª«Éó¨î¥Î¤_药ª«开发ªº¬ã¨s¥¿¦b±À进¤§¤¤¡C¤é¥»ªºªì创¥ø业计¦E¤_2024¦~开©l针对¿}§¿¯f©M¯«经¨t
统ºÃ难¯e¯f进¦æ临§É试验¡C¬ã¨sªí©ú¡A现¦³药ª«ªº§@¥Î¤]ÉO内质ÊI应¿E¤Ï应Éó¨î¦³关¡C阐©ú该Éó¨îªº¤é¥»¬ã¨s¤H员³Q视为
诺贝ûØ奖Ô选¤H¡A该Éó¨î¤]³Q视为¦³«e´ºªºªv疗¹v点¦Ó备¨ü瞩¥Ø¡C
内质ÊI¦b细M¤¤¥R当¦X¦¨³J¥Õ质ªº¤uÉD¡C¦pªG³J¥Õ质ªº¡§¦¸«~¡¨²Ö积产¥Í¡§应¿E¡¨¡A会诱导×Î`©Î¥h°£该³J¥Õ质ªº¡§¤Ï应¡¨¡C¨Ê
³£¤j学´Ë©M«T±Ð±Â阐©ú¤F¤WzÊ^内³J¥Õ质«~质ªººÞ²zÉó¨î¡A¦}¤_2014¦~ýU获¬ü国©Ô´µ§J奖¡A该奖项³Q视为诺贝ûØ奖ªº风¦V
标¡K¡K
2.¤º½èºô¹v¦V§í¨î CYP2E1´î»´¨x²ÓM®ñ¤ÆÀ³¿E©M°fÂà°sºë©Ê¨x¯f(CMZ@ER-NEs纳¦Ì§Þ术)
·|û¡GROGER588910148151 µoªí®É¶¡:2022/10/30 ¤W¤È 10:55:32²Ä 2648 ½g¦^À³
2022.8.31µØªF5¤j¦W®Õ®ý¦¿¤j¾Ç³Ì·s¬ã¨s¡GCMZ@ER-NEs纳¦Ì§Þ术¦³±æ°f转°sºë©Ê¨x¯f
www.toutiao.com/article/7138028614150423055/
3.2021.9.22 ©¬ª÷´Ë¯fªº·sÃĪ«¹vÂI: ¤º½èºô(ER)À³¿E½Õ¸`¾¯
content.iospress.com/articles/journal-of-parkinsons-disease/jpd212673
4. html.rhhz.net/GJSJBX/2014-2-164.htm
内质ÊIÉO线²ÉÊ^¥\¯à
内质ÊIÉOROS (®ñ¤Æ应¿E)
5.CYP2E1 ¦b¸£¤ºÃĪ«¥NÁ©Υͪ«¿E¬¡¤¤ªº§@¥Î
www.ncbi.nlm.nih.gov/pmc/articles/PMC5259652/
RPD Designation Program Sunset Provisions
On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended. Under the current statutory sunset provisions, after September 30, 2024, FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, FDA may not award any rare pediatric disease priority review vouchers.
For any questions, please contact the Office of Orphan Products Development at orphan@fda.hhs.gov.
³o®a¤½¥q¦¨¥ß9¦~¤~¤W¿³Âd. è¶}©l³o¤½¥q¦P®É¶i¦æ3¸ô²£«~½u. ¦P®É¤S¤À¤ß¥´ºâ°ê¥~¤W¥«.
µ²ªG3±ø½u³£°µ¤£¥X¦¨ªG. °ê¥~¤W¥«¤]®À§é. ®tÂI¸êª÷¬yÂ_Ãì.
«á¨Ó§ïÅÜ°µªk, ©ñ±ó2±ø²£«~½u. ±Mª`1±ø. ³o1²£«~½u¦³3ºØ¥\¯à, ¤]¥u±Mª`1ºØ. ¨M©w¥xÆW¤W¿³Âd,¥¼¨Ó¥xÆW¤WÂd.
µ²ªG¥h¦~¦¨¥\¤W¿³Âd. ªÑ¥»»P6634 ¬Û·í, ²£«~¥«³õ¤£¤Î6634 ªº¥i¯à1/3©Î1/4. ¥Ø«eªÑ»ù¥«6634ªº2¿. ¸Ó¤½¥q²{¦b¥´ºâ2024 Q2±Mª`§¹¦¨2b.²{¦b¤w¸g¿n·¥½Í±ÂÅv. ¹wpÁ{¤G§¹¦¨«á, ±ÂÅvª÷6-8.8»õ¬üª÷. ³Ì±ß2024Âà¤WÂd.
¦ÑÁó¸òªk¤H»¡·Qn´X¦~«á(¤]³\10¦~), ±N¤½¥q¥H100»õ¬üª÷½æµ¹°ê¥~Ãļt.
µ²½×:
1.¥ý±Mª`³Ì©ú¬P²£«~.
2.¥þ¤O½Í±ÂÅv.
©t¨àºÙ¸¹¡G ªvÀø±w¦³ÂX±i«¬¤ß¦Ù¯fªº¨à¬ì±wªÌ¡]0 ¦Ü 16 ·³¡^¡C
¤W¥«§åã¤é´Á¡G 2019-04-22
§å㪺¼ÐÅÒ¾AÀ³¯g¡G Corlanor ¾A¥Î©óªvÀø 6 Ó¤ë¤Î¥H¤WªºÄu©Ê¤ß«ß¦ñ¤ß²v¤É°ªªºÂX±i«¬¤ß¦Ù¯f (DCM) ¤Þ°_ªºÃ©w¯gª¬©Ê¤ß¤O°IºÜ¡C
----------------------------------------------------------------------------------------------
¬JµMªvÀøÃh¥¥°ü¤kªº¯f¤Ó³Â·Ð¡A³oÓªvÀø¤p¨àDCM¯fÀ³¸Ó¬O¥i¥H¦a(¤£ª¾ªYÄ£§ä¹L¨S?)
¤µ¦~¤@Ó¦³ÂI·N«äªº±ÂÅv®×¡A4Ó¤ë¤@¨Ó¤@©¹®t»ù14»õ¬ü¤¸!
2023.1.25
www.drugtimes.cn/2023/01/25/yigelinchuangshiyandeshibaiweiasilikangshengxia14yimeiyuanci/
2018¦~¡A§A开¤F¤@®a¤½¥q¡A4¦~从¥¼¬Õ§Q¡AúÒ°µ¥X¤F¤@´Ú®Ö¤ß产«~¡C
¤@¦ì¤j¨Ð±oª¾¦Z¡A¦V§A´£¥X¦¬购¡]11亿¬ü¤¸¡^¡A§A¤£ªÖ¡A说钱¤£¤Óû{¡C
¤£¤[¦Z¡A§A带领¤½¥q¤W¥«¡Aú«É®Ö¤ß产«~¡AªÑɲ¼É涨¡A¥«È½µf¡C
¨º¦ì¤j¨Ð¦A¦¸§ä¨ì§A¡A¦A´£¦¬购¡A这¦¸¬O32亿¬ü¤¸¡A§A¤£ªÖ¡A说钱¤£¤Óû{¡C
¥i¦n´º¤£长¡A2个¤ë¦Z¡A§Aªº®Ö¤ß产«~¥X现问题¡A导PªÑɲ¼É¶^¡A¥«ÈÀþ间»]发ªñ¤@¥b¡C
还¬O¨º¦ì¤j¨Ð¡A还¬O¸ò§A´£¦¬购¡A¥u¤£过¥L这¦¸¥uã备¤F15亿¬ü¤¸¡A§AúÒ说¡A¥i¥H谈谈¡C
³Ì¦Z¡A§A们¥H18亿¬ü¤¸ªºÉ²®æ达¦¨¦X§@¡A¥|个¤ë¡A§A亏¤F14亿¬ü¤¸¡C
§A´N¬OCincor¡A¤@®a专ª`¤_难ªv©Ê°ª¦å压©MºC©Ê肾¯fªºBiotech¡C
¨º¦ì¤j¨Ð¡A¥sªü´µ§Q±d¡C
18_Q&A_¤G´Á®³ÃÄÃÒ
www.facebook.com/100064104724409/videos/443452154155295?__so__=permalink
1¤À30¬í~ JP:§ÚÌÃĤ]¦b§V¤O¦a§ä...¥i¬O...§ÚÌ«á¨Ó§ä¨ì¤@ÓÃh¥¥°ü¤k¤~·|¦³ªº¯f §ÚÌ´N¤£¸I ¦]¬°Ãh¥¥°ü¤k¤Ó³Â·Ð...
--------------------------------------------------------------------------------------------------
JP»¡ªºÀ³¸Ó¬O:SNP-610¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x
CYP2E1ªvÀø¤p¨à¤ß¦Ù¯fÅÜ???
«ü¤ßŦ¦Ù¦×¥\¯à²§±`¡A¾ÉP¤ßŦÂX¤j¦Ó¥B¤ß«Ç¦¬ÁY¥\¯àÅÜ®t¡A¬O[¤p¨à]¤ß¦Ù¯fÅܤ¤³Ì±`¨£ªº¤@ºØ¡C¤j³¡¤À¬°ìµo©Ê¡A¤Ö³¡¤À¦]¨ä¥L¯e¯f¦Ó¤Þ°_¡C
-------------------------------------------------------------------------------------------------
JP»¡n§äÓ©t¨àÃľAÀ³¯g¥[³t¶}µo....¡A¦³¤H¤O´N±´¨sCYP2E1ªvÀø¤p¨à¤ß¦Ù¯fÅܬOӿﶵ!
¨ú±o¬ü°êFDAªº¡u¨u¨£¨à¬ì¯e¯f»{©w¡v¡]RPD¡^ªÌ¡A±N¯Ç¤J¬ü°êFDA¡uÀu¥ý¼f®Ö¾ÌÃÒpµe¡v¡A¦¹pµe¦®¦b¹ªÀyÃļt¶}µo¨u¨£¨à¬ì¯e¯f¥ÎÃÄ¡AÀò¦¹»{©wªº·sÃÄ¡A¦bÀòã¤W¥««á§Y¥i¨ú±o¡uÀu¥ý¼f®Ö¾ÌÃÒ¡v¡]PRV¡^¡C---³o±i¾ÌÃÒ¥«»ù>1»õ¬ü¤¸!
ÅçÃÒ©Ê2´Á
¦pªG¦³ÂIpµeªº¸Ü
1´ÁÁö¬O¦w¥þ©Ê¸ÕÅç
ÁÙ¬O¥i¥H¦¬¶°¨ì¤@¨Ç·Qnªº¥Í¤Æ«ü¼Æ
®Ú¾Ú³o¨Ç¸ê°T¥h³]p2´Á
R¤j©Ò«üªº¡u²æ¿Ç¤l©ñ§¾¡v¤j·§¬O®Ú¥»¨S¦³¥²n¥h°µ¨ºÓ2a¡C
106¦~´Nã2´Á¡A¦³¥ø¹Ï¤ß¡A²{¦b³£¨ì3´Á¤F¡I
§Ú³£¨S¥D·N¨ì
2021.12.18 cn.lillyasiaventures.com/blog/biomarin
¤E¤Ñ¥Íª«ÉO¬ü国BioMarin¨î药¤½¥q达¦¨¥þ²y战²¤¦X§@¡A为¤ß¦åºÞ¯e¯f开发创·s°ò¦]疗ªk
关¤_扩张«¬¤ß¦Ù¯f (DCM)
扩张«¬¤ß¦Ù¯f¬O导P¤ß¤O°IºÜªº±`见ì¦]¡A扩张«¬¤ß¦Ù¯f发®i¨ì¥½´Á±`»Ýn¤ß脏²¾´Ó¡C尽ºÞ药ª«ªv疗©M护²z¦³©Ò§ïµ½¡A¦ý该¯e¯f 5 ¦~¥Í¦s²v约为 50%¡C¦b¬ü国¡B欧·ù¡B¤¤国©M¤é¥»µ¥¦a区¦³数¤QÉE±wªÌ¿©±w遗传©Ê扩张«¬¤ß¦Ù¯f¡C¬Û关¬ã¨s¤w发现 50 ¦h个¥i¯à导P扩张«¬¤ß¦Ù¯fªº°ò¦]¬ð变¡A¥e®a±Ú©Ê扩张«¬¤ß¦Ù¯f¯f¨Òªº40-50%¡C¨ä¤¤¦³许¦h°ò¦]编码ªº³J¥Õ质¦b¤ß¦Ù细M¤¤¨ã¦³«nªº¥\¯à¡A¥]¬A细M°©¬[¡B¦Ù节©M®Ö¥]½¤³J¥Õ¡C§Ú们ªº¥Ø标¬O§Q¥Î°ò¦]ªv疗§Þ术纠¥¿这¨Ç导PDCMªº遗传¦]¯À¡A针对¨C个¨ãÊ^¯e¯f¸Ñú¨¨ä®Ú¥»P¯fì¦]¡C
ªYÄ£¦b§í¨îCYP2E1¬O±j¶µ¡AÂX±i©Ê¤ß¦Ù¯fDCM¤]¦n¦nµo´§§a!(¾Ú§ÚÌ©Òª¾¡A¨ì¥Ø«e¬°¤îÁÙ¨S¦³¬ÛÃö¬ã¨sªº³ø¾É)
-------------------------------------------------------------------------------------------------
§Úªº¥Î·N¦bSNP-810±ÂÅv(§í¨îCYP2E1)®É¥i¯Ç¤J¦Ò¶q....(²¦³º¤§«e¨S¦³CYP2E1ªvÀø¤ßŦ¯fªº¬ã¨s)
¦ÓJ&J¥Î166»õ¬ü¤¸¦¬ÁÊAbiomed ¡A¹ï³o¶ô²j¯àµL¿³½ì!!!
¦n¹³¬Oºô¶§ó·s«á¬Ý¨ìªº
810ªº³¡¤À¼g¤F¤@°ï
TO-R¤j
²{¶¥¬q³Ì«æ¢ªº¥Ø¼Ð¡A¬OÃ@µ¦¤½¥q»°§Ö§¹¦¨810¡B610¸ÕÅç¡C
¤×¨ä¬O610¥Ø«e¬O¨«¦b®öÀY¤W
80¤Hªº¸ÕÅç¯un»°¶i«×¡A¦hµ¹Âå°|¼úª÷¡A3Ó¤ë¥ÎÃÄ¡A«Ü§Ö´N·|§¹¦¨¡C
¤½¥qªº¦~³øÅã¥ÜM¤½¥q3´Án¨ì2024¦~¡A¤H®a2022/12´N¤½¥¬µ²ªG¡C
80¤H¬O¬dÅçµn°O¥ÎÁ{§É
------------------------------------------
½Ð°Ýr¤j³o¥y¸Ü¦b¦ó³B¬Ý¨ìªº©O¡H
2022.11.1 ¼b¥Í¤½¥q¥H166»õ¬ü¤¸¦¬ÁÊAbiomed ¥HÂX¤j¨ä¤ß¦åºÞ·~°È(°w¹ï«æ©Ê¤ßŦ°IºÜ±wªÌ´£¨Ñ¤ßŦ´_µd´`Àô¤ä«ù¤Î«ùÄò·ÓÅ@¤§ÂåÀø¾¹§÷ªº¬ã¨s¡B¶}µo¤Î¾P°â)
----------------------------------------------------------------------------------------------
1. 2019¦~ www.sciencedirect.com/science/article/pii/S0925443918303028
...³o¨Çµo²{º¦¸´¦¥Ü Akt2 ¥\¯à¤£¥þ¥i¯à³q¹L CYP2E1 ¤¶¾Éªº¾÷¨î«P¶i¥NÁ©ʤߦٯfªºµo®i¡Aªí©ú CYP2E1 ¦b¥NÁ©ʤß
¦Ù¯fºÞ²z¤¤ªºªvÀø¼ç¤O¡C
2. 2021¦~ www.spandidos-publications.com/10.3892/mmr.2021.12492
...³o¨Çµo²{ÁÙªí©ú¡A§í¨î CYP2E1 ¥i¯à¬O±±¨î¤ßŦ¯fµo®iªº¤@ºØ¦³»ùȪºªvÀøµ¦²¤¡A¤×¨ä¬O¨º¨Ç»P CYP2E1 ¤W½Õ¬ÛÃöªº¯e
¯f¡C
¦¹¥~¡A¥Ñ©ó CYP2E1 ¬O²ÓM©M½u²ÉÅé ROS/RNS ªº¥Dn¨Ó·½¡A§í¨î CYP2E1 ¥i¯à·|§ïµ½ DCM ªº¯f²z¾v®i¡C¤Wz¬ã¨sªí©ú¡A§í¨îCYP2E1¥i¯à§ïµ½DCMªº¯f²z¾v®i¡ACYP2E1§í»s¾¯ªºÀ³¥Î¥i¯à¦¨¬°¤@ºØ¦³®ÄªºªvÀø¤â¬q¡FµM¦Ó¡A¾Ú§ÚÌ©Òª¾¡A¨ì¥Ø«e¬°¤îÁÙ¨S¦³¬ÛÃö¬ã¨sªº³ø¾É¡C